Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
== Mission and Research Strategy == The mission of TBRI is targeted towards the control, the diagnosis and management of endemic diseases and their complications especially those affecting the liver, the gastrointestinal and the urinary tracts, mainly as result of schistosomiasis and viral hepatitis, this is to meet the social, economic and technological needs of Egypt and the regional area. The Institute adopts an integrated strategy based on six research programs that can cope with and fulfill this objective:
=== Trypsin === While working in the laboratory of Max Bergmann at Rockefeller Institute, now Rockefeller University, Hofmann synthesized analogs of the amino acid lysine and proved that the enzyme trypsin cleaves linkages involving the carboxyl group of that amino acid.
== History == The condition was first described in 1561 in correspondence between Andreas Vesalius and Gabriele Falloppio and separately by Gabriele Falloppio. The condition is named after François Gigot de la Peyronie, who described it in 1743. Peyronie was the personal physician of King Louis XV and cofounder of the Académie Royale de Chirurgie, which was later included in the French Académie nationale de médecine.
=== Early modern era === The Portuguese planted fruit trees and vegetables on Saint Helena, a stopping point for homebound voyages from Asia, and left their sick who had scurvy and other ailments to be taken home by the next ship if they recovered. These travel accounts did not prevent further maritime tragedies caused by scurvy, partly because of the lack of communication between travelers and those responsible for their health, and because fruits and vegetables could not be kept for long on ships. In the 1519-1521 circumnavigation, Magellan's crew suffered from scurvy: "above all other calamities this was the worst: in some men the gums grew over the teeth, both lowers and uppers, so that they could not eat in any way and thus they died of this sickness. Nineteen men died." In 1536, the French explorer Jacques Cartier, while exploring the St. Lawrence River, used the local St. Lawrence Iroquoians' knowledge to save his men dying of scurvy. He boiled the needles of the aneda tree (generally believed to have been eastern white cedar) to make a tea that was later shown to contain 50 mg of vitamin C per 100 grams. Such treatments were not available aboard ship, where the disease was most common. Later, possibly inspired by this incident, several European countries experimented with preparations of various conifers, such as spruce beer, as cures for scurvy. In 1579, the Spanish friar and physician Agustin Farfán published a book in which he recommended oranges and lemons for treating scurvy, a remedy that was already known in the Spanish navy.
Sources: en.wikipedia.org
=== Logic === Formal logic is used for reasoning and knowledge representation. Formal logic comes in two main forms: propositional logic (which operates on statements that are true or false and uses logical connectives such as "and", "or", "not" and "implies") and predicate logic (which also operates on objects, predicates and relations and uses quantifiers such as "Every X is a Y" and "There are some Xs that are Ys"). Deductive reasoning in logic is the process of proving a new statement (conclusion) from other statements that are given and assumed to be true (the premises). Proofs can be structured as proof trees, in which nodes are labelled by sentences, and children nodes are connected to parent nodes by inference rules. Given a problem and a set of premises, problem-solving reduces to searching for a proof tree whose root node is labelled by a solution of the problem and whose leaf nodes are labelled by premises or axioms. In the case of Horn clauses, problem-solving search can be performed by reasoning forwards from the premises or backwards from the problem. In the more general case of the clausal form of first-order logic, resolution is a single, axiom-free rule of inference, in which a problem is solved by proving a contradiction from premises that include the negation of the problem to be solved. Inference in both Horn clause logic and first-order logic is undecidable, and therefore intractable. However, backward reasoning with Horn clauses, which underpins computation in the logic programming language Prolog, is Turing complete.
In early November 1938, under the First Vienna Award, which was a result of the Munich agreement, Czechoslovakia—which had failed to reach a compromise with Hungary and Poland—had to cede after the arbitration of Germany and Italy awarded southern Slovakia and Carpathian Ruthenia to Hungary, while Poland invaded Trans-Olza territory shortly after. As a result, Bohemia, Moravia and Silesia lost about 38% of their combined area to Germany, with some 3.2 million German and 750,000 Czech inhabitants. Hungary, in turn, received 11,882 km2 (4,588 sq mi) in southern Slovakia and southern Carpathian Ruthenia; according to a 1941 census, about 86.5% of the population in this territory was Hungarian. Meanwhile, Poland annexed the town of Český Těšín with the surrounding area (some 906 km2 (350 sq mi)), some 250,000 inhabitants, Poles making up about 36% of population, and two minor border areas in northern Slovakia, more precisely in the regions Spiš and Orava. (226 km2 (87 sq mi), 4,280 inhabitants, only 0.3% Poles). Soon after Munich, 115,000 Czechs and 30,000 Germans fled to the remaining rump of Czechoslovakia. According to the Institute for Refugee Assistance, the actual count of refugees on 1 March 1939 stood at almost 150,000. On 4 December 1938, there were elections in Reichsgau Sudetenland, in which 97.32% of the adult population voted for the National Socialist Party. About 500,000 Sudeten Germans joined the National Socialist Party, which was 17.34% of the German population in Sudetenland (the average National Socialist Party participation in Nazi Germany was 7.85%).
Dialkylbiaryl phosphine ligands are phosphine ligands that are used in homogeneous catalysis. They have proved useful in Buchwald-Hartwig amination and etherification reactions as well as Negishi cross-coupling, Suzuki-Miyaura cross-coupling, and related reactions. In addition to these Pd-based processes, their use has also been extended to transformations catalyzed by nickel, gold, silver, copper, rhodium, and ruthenium, among other transition metals.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.